Abstract
The Chairman opened the session with some comments on targets for new platinum drugs. Although the field of platinum based anti-cancer drugs has developed enormously since the pioneering work of Dr. Barnett Rosenberg, it is important to keep a sense of perspective. Cisplatin is very toxic, not well tolerated and is active against a limited number of tumour types, being only regularly curative in one (testicular). The classification produced by Durant at the Atlanta meeting (Table 1) still represents the clinical contribution of cisplatin today. The need to search for more tumour specific platinum and other metal based drugs is as strong now as it was in 1970 when structure activity studies first got underway.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishing, Boston
About this chapter
Cite this chapter
Cleare, M.J. (1984). Overview. In: Hacker, M.P., Douple, E.B., Krakoff, I.H. (eds) Platinum Coordination Complexes in Cancer Chemotherapy. Developments in Oncology, vol 17. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2837-7_17
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2837-7_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-89838-619-6
Online ISBN: 978-1-4613-2837-7
eBook Packages: Springer Book Archive